HARNACK U[au] - Search Results

Year	Number of Results
2001	2
2004	2
2008	2
2009	1
2010	2
2011	4
2018	2
2024	0

1

Impact of antigen-unloaded immature dendritic cells on antileukemic T-cell cytotoxicity.

Harnack U, Pecher G. Harnack U, et al. Anticancer Res. 2008 Sep-Oct;28(5A):2831-5. Anticancer Res. 2008. PMID: 19035318 Free article.

2

Yeast-derived beta-(1-3),(1-6)-D-glucan induces up-regulation of CD86 on dectin-1-positive human B-lymphoma cell lines.

Harnack U, Kellermann U, Pecher G. Harnack U, et al. Anticancer Res. 2011 Dec;31(12):4195-9. Anticancer Res. 2011. PMID: 22199280

3

Beta-(1-3),(1-6)-D-glucan enhances the effect of low-dose cyclophosphamide treatment on A20 lymphoma in mice.

Harnack U, Eckert K, Pecher G. Harnack U, et al. Anticancer Res. 2011 Apr;31(4):1169-72. Anticancer Res. 2011. PMID: 21508361

4

Natural killer cell line YT exerts cytotoxicity against CD86+ myeloma cells.

Harnack U, Johnen H, Pecher G. Harnack U, et al. Anticancer Res. 2011 Feb;31(2):475-9. Anticancer Res. 2011. PMID: 21378326

5

Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts.

Goletz C, Lischke T, Harnack U, Schiele P, Danielczyk A, Rühmann J, Goletz S. Goletz C, et al. Among authors: harnack u. Front Immunol. 2018 Jul 16;9:1614. doi: 10.3389/fimmu.2018.01614. eCollection 2018. Front Immunol. 2018. PMID: 30061887 Free PMC article.

6

Role of soluble β-(1-3),(1-6)-D-glucan from Saccharomyces cerevisiae in the murine P388 ascites tumor model.

Harnack U, Eckert K, Pecher G. Harnack U, et al. In Vivo. 2011 Mar-Apr;25(2):185-9. In Vivo. 2011. PMID: 21471533

7

Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.

Menssen HD, Harnack U, Erben U, Neri D, Hirsch B, Dürkop H. Menssen HD, et al. Among authors: harnack u. J Cancer Res Clin Oncol. 2018 Mar;144(3):499-507. doi: 10.1007/s00432-017-2564-6. Epub 2018 Jan 11. J Cancer Res Clin Oncol. 2018. PMID: 29327244

8

Quantification of the CD8+ T cell response against a mucin epitope in patients with breast cancer.

Kokowski K, Harnack U, Dorn DC, Pecher G. Kokowski K, et al. Among authors: harnack u. Arch Immunol Ther Exp (Warsz). 2008 Mar-Apr;56(2):141-5. doi: 10.1007/s00005-008-0011-8. Epub 2008 Mar 31. Arch Immunol Ther Exp (Warsz). 2008. PMID: 18373244 Free PMC article.

9

IL-1 receptor antagonist anakinra enhances tumour growth inhibition in mice receiving peptide vaccination and beta-(1-3),(1-6)-D-glucan.

Harnack U, Johnen H, Pecher G. Harnack U, et al. Anticancer Res. 2010 Oct;30(10):3959-65. Anticancer Res. 2010. PMID: 21036709

10

Comparison of the effect of orally administered soluble beta-(1-3),(1-6)-D-glucan and of G-CSF on the recovery of murine hematopoiesis.

Harnack U, Eckert K, Fichtner I, Pecher G. Harnack U, et al. In Vivo. 2010 Jan-Feb;24(1):59-63. In Vivo. 2010. PMID: 20133977

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

15 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year